Development of any (cavitated or non-cavitated) carious lesion · Children younger than 6 years with caries-free primary dentition (no cavitated or non-cavitated lesions at baseline)
Preschool children with mutans streptococci at baseline probably have about four times higher odds of developing early childhood caries (OR 4.13; moderate certainty).
10 findings from 1 review
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes6 months to 3.5 years · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Overall
OR 4.13 [3.33, 5.12]
12 studies · 3010 participants
Moderate
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes6 months to 3.5 years · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Sample: plaque
OR 5.16 [2.99, 8.91]
5 studies · 736 participants
GRADE not reported
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes6 months to 3.5 years · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Sample: saliva
OR 3.92 [3.20, 4.80]
9 studies · 2577 participants
GRADE not reported
Show 7 more findings
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes1 year · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Follow-up: 1 year
OR 4.37 [3.50, 5.45]
4 studies · 2016 participants
GRADE not reported
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes2.7 years (31 months median) · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Follow-up: 2.7 years (31 months median)
OR 33.00 [3.18, 342.26]
1 study · 28 participants
GRADE not reported
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes2 years · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Follow-up: 2 years
OR 2.53 [1.22, 5.23]
4 studies · 297 participants
GRADE not reported
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes6 months to 3.5 years · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Microbiological assessment: quantitative (culture/CFU counting)
OR 3.82 [2.01, 7.26]
6 studies · 732 participants
GRADE not reported
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes3.5 years (42 months) · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Follow-up: 3.5 years (42 months)
OR 4.23 [2.49, 7.18]
1 study · 366 participants
GRADE not reported
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes6 months · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Follow-up: 6 months
OR 4.65 [2.01, 10.76]
2 studies · 303 participants
GRADE not reported
Is Mutans Streptococci count a risk predictor of Early Childhood Caries? A systematic review and meta-analysis. 2023 All outcomes6 months to 3.5 years · Caries-free preschool children (<6 y), primary dentition; community/clinic; studies from Japan, Finland, USA, Sweden and Singapore · Microbiological assessment: semi-quantitative (Dentocult/commercial kit)
OR 4.36 [3.53, 5.39]
6 studies · 2278 participants
GRADE not reported
Future caries experience (dmft/dmfs) · Children younger than 6 years with caries-free primary dentition (no cavitated or non-cavitated lesions at baseline)
Children with mutans streptococci at baseline had a greater future caries experience (SMD 0.85, a large effect; ungraded).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
1 finding from 1 review
Adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review